Coeptis Therapeutics (NASDAQ:ZSQR) Shares Down 9% – Should You Sell?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) traded down 9% during mid-day trading on Wednesday . The company traded as low as $9.99 and last traded at $10.14. 93,545 shares were traded during mid-day trading, a decline of 2% from the average session volume of 95,250 shares. The stock had previously closed at $11.14.

Coeptis Therapeutics Price Performance

The stock has a market capitalization of $560.07 million, a price-to-earnings ratio of -4.32 and a beta of -0.22. The stock has a 50-day moving average price of $11.95 and a 200 day moving average price of $13.19. The company has a current ratio of 3.25, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01.

Coeptis Therapeutics (NASDAQ:ZSQR) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%. The business had revenue of $0.11 million during the quarter.

Hedge Funds Weigh In On Coeptis Therapeutics

A number of large investors have recently added to or reduced their stakes in ZSQR. Steward Partners Investment Advisory LLC raised its position in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the period. Yorkville Advisors Global LP acquired a new position in Coeptis Therapeutics during the third quarter worth $140,000. Marshall Wace LLP acquired a new stake in Coeptis Therapeutics in the 4th quarter worth about $259,000. State Street Corp boosted its holdings in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares during the last quarter. 13.88% of the stock is currently owned by institutional investors and hedge funds.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.